Indications
Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
Composition
- Active substance
- pixantrone dimaleate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pixuvri
- Active substance
- pixantrone dimaleate
- ATC code
- L01DB11
- Therapeutic area
- Lymphoma, Non-Hodgkin
- Marketing authorisation holder